Monsanto kept name lists for several European countriesBayer said that Monsanto's lists of supportive and critical stakeholders on pesticides covered not only France but also Germany, Italy, Netherlands, Poland, Spain, and UK as well as stakeholders related to EU institutions, FAZ (p25) and Sueddeutsche (p17) reported on Wednesday and Handelsblatt (p22-23) on Thursday.
Health Ministry's legislation to increase costs for health insurersThe current and future legislation projects by the Health Ministry could lead to increasing costs for statutory health insurers that would affect all insurees, SZ reports on Friday (p17).
German pharma lagging behind in international competitionThe major German pharma companies are lagging behind international competitors, according to an EY report, FAZ (p20) and SZ (p17) said on Tuesday.
Narasimhan is Novartis' 'golden boy'Weekly Manager Magazin on Friday (p38-42) portrays Novartis's chief executive Vas Narasimhan as the company's "golden boy", who "sees his job as a mission".
Fresenius has no plans for major acquisitionsFresenius is not planning any major acquisitions in the near future, reported FAZ on Saturday (p22).
Evotec buys U.S. biologics specialist Just BiotherapeuticsGerman biotech Evotec is planning to buy U.S. biologics specialist Just Biotherapeutics for up to $90 million in cash, reported FAZ on Wednesday (p21).
Abacus's second attempt to float in GermanyDanish pharmaceutical importer Abacus Medicine is making a second attempt to become a public company, Handelsblatt says on Friday (p37).
Major payer launches electronic patient fileMajor German health insurer TK launched the first nationwide payer-managed electronic patient file on Monday, reported FAZ on Monday (p18).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.